ARCHIVES

Hospital to Review Medenica’s Privileges, With Conditions

This article is from The Cancer Letter archive.

Vol. 19 No. 43 | November 5, 1993

Download PDF Visit The Full Archive

Related Articles

BMS, ImClone To Develop New Drug IMC-C225, Targets EGF Receptor.

September 28, 2001

Authorizes $2.7 Billion For NCI, 7% Prevention

May 28, 1993

Neutron Therapy Contracts Wind Down Next Year; DCT To Consider Whether To Continue Support

March 25, 1988

SAIC Begins Transition Of Frederick Operations From Incumbent PRI

March 17, 1995

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

NCI Bid For New Clinical Review Panel Rejects; But Invites Researchers To ‘Submit Best Ideas’

March 8, 1991